BlueWillow Biologics

Primary contact

Formerly known as NanoBio, BlueWillow Biologics, Inc. is a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform. BlueWillow's technology uses proprietary nano-scale formulations to enable numerous dermatology products as well as a broad range of drug delivery applications. The technology employs high-energy, oil-in-water emulsions. The resulting products are composed of droplets roughly 200nm in size that use a physical process to disrupt the outer lipid membrane of viruses, bacteria and fungi. BlueWillow's lead product candidates include intranasal vaccines for RSV, seasonal and pandemic influenza, pertussis, anthrax, HSV-2 and chlamydia.
Primary contact

Funding 💰

Total $92.8M
Select investors Centre Lane Partners, North Coast Technology Investors, Venture Investors, National Institute Of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation
Last update: May 14, 2018